A. Hause

发表

Safety Monitoring of COVID-19 mRNA Vaccine First Booster Doses Among Persons Aged ≥12 Years with Presumed Immunocompromise Status — United States, January 12, 2022–March 28, 2022

T. Shimabukuro, J. Baggs, W. Abara, 2022, MMWR. Morbidity and mortality weekly report.

Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years — United States, August 31–October 23, 2022

P. Blanc, T. Shimabukuro, John R Su, 2022, MMWR. Morbidity and mortality weekly report.

Safety Monitoring of COVID-19 mRNA Vaccine Second Booster Doses Among Adults Aged ≥50 Years — United States, March 29, 2022–July 10, 2022

P. Blanc, T. Shimabukuro, J. Baggs, 2022, MMWR. Morbidity and mortality weekly report.

Safety Monitoring of an Additional Dose of COVID-19 Vaccine — United States, August 12–September 19, 2021

D. Shay, T. Shimabukuro, J. Baggs, 2021, MMWR. Morbidity and mortality weekly report.

Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults — United States, September 22, 2021–February 6, 2022

E. Woo, P. Blanc, T. Shimabukuro, 2022, MMWR. Morbidity and mortality weekly report.

COVID-19 Vaccine Safety in Adolescents Aged 12–17 Years — United States, December 14, 2020–July 16, 2021

D. Shay, T. Shimabukuro, J. Baggs, 2021, MMWR. Morbidity and mortality weekly report.

Reactogenicity of Simultaneous COVID-19 mRNA Booster and Influenza Vaccination in the US

D. Shay, T. Shimabukuro, Xin Yue, 2022, JAMA network open.

COVID-19 Vaccine Safety in Children Aged 5-11 Years - United States, November 3-December 19, 2021.

D. Shay, T. Shimabukuro, J. Baggs, 2021, MMWR. Morbidity and mortality weekly report.

Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12–17 Years — United States, December 9, 2021–February 20, 2022

T. Shimabukuro, J. Baggs, John R Su, 2022, MMWR. Morbidity and mortality weekly report.

Findings of long-term depression up to 8 years post infection from West Nile virus.

K. Murray, Melissa S. Nolan, A. M. Hause, 2012, Journal of clinical psychology.

Prevalence of Chronic Kidney Disease and Progression of Disease Over Time among Patients Enrolled in the Houston West Nile Virus Cohort

K. Murray, K. Finkel, Amber S. Podoll, 2012, PloS one.

Menstrual irregularities and vaginal bleeding after COVID-19 vaccination reported to v-safe active surveillance, USA in December, 2020–January, 2022: an observational cohort study

Karen K. Wong, C. Olson, C. Heilig, 2022, The Lancet Digital Health.

The v-safe after vaccination health checker: Active vaccine safety monitoring during CDC’s COVID-19 pandemic response

C. Olson, T. Shimabukuro, J. Gee, 2023, Vaccine.

Evaluation of prolonged fatigue post-West Nile virus infection and association of fatigue with elevated antiviral and proinflammatory cytokines.

J. Orange, K. Murray, R. Hasbún, 2014, Viral immunology.

Epidemiology of Dengue among Children Aged < 18 Months—Puerto Rico, 1999–2011

H. Margolis, J. Aiwazian, K. Tomashek, 2016, American Journal of Tropical Medicine and Hygiene.

Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B

C. Shaw, P. Piedra, A. M. Hause, 2017, PloS one.

Respiratory Syncytial Virus (RSV): Neutralizing Antibody, a Correlate of Immune Protection.

P. Piedra, A. M. Hause, Letisha Aideyan, 2016, Methods in molecular biology.

Safety Monitoring of Pfizer-BioNTech COVID-19 Vaccine Booster Doses Among Children Aged 5–11 Years — United States, May 17–July 31, 2022

T. Shimabukuro, J. Baggs, John R Su, 2022, MMWR. Morbidity and mortality weekly report.

Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5–11 Years — United States, October 12–January 1, 2023

T. Shimabukuro, John R Su, J. Gee, 2023, MMWR. Morbidity and mortality weekly report.

Safety of COVID-19 Vaccination in US Children Ages 5-11 Years.

J. Glanz, Joshua T. B. Williams, B. Fireman, 2022, Pediatrics.

Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe

T. Shimabukuro, M. McNeil, L. Markowitz, 2022, The Lancet Infectious Diseases.

Safety Monitoring of mRNA Vaccines Administered During the Initial 6 Months of the U.S. COVID-19 Vaccination Program: Reports to Vaccine Adverse Events Reporting System (VAERS) and v-safe

D. Shay, D. Menschik, T. Shimabukuro, 2021, medRxiv.

Clinical characteristics and outcomes of respiratory syncytial virus infection in pregnant women

P. Piedra, F. Muñoz, X. Ye, 2019, Vaccine.

A Cross-sectional Surveillance Study of the Frequency and Etiology of Acute Respiratory Illness Among Pregnant Women

P. Piedra, F. Muñoz, M. Maccato, 2018, The Journal of infectious diseases.

COVID-19 mRNA Vaccine Safety Among Children Aged 6 Months–5 Years — United States, June 18, 2022–August 21, 2022

T. Shimabukuro, John R Su, J. Gee, 2022, MMWR. Morbidity and mortality weekly report.

D. Shay, T. Shimabukuro, John R Su, 2021, MMWR. Morbidity and mortality weekly report.

Association Between Vaccine Exemption Policy Change in California and Adverse Event Reporting

S. Omer, M. McNeil, P. Marquez, 2020, The Pediatric infectious disease journal.

Adverse Outcomes in Pregnant Women Hospitalized with Respiratory Syncytial Virus Infection: A Case-Series.

E. Weintraub, H. Tseng, L. Sy, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

COVID-19 Vaccine Safety First Year Findings in Adolescents.

S. Maloney, T. Shimabukuro, M. Cortese, 2023, Pediatrics.

Dashboard development for near real-time visualization of COVID-19 vaccine safety surveillance data in the Vaccine Safety Datalink

J. Nelson, E. Weintraub, K. Hanson, 2022, Vaccine.

Association between history of SARS-CoV-2 infection and severe systemic adverse events after mRNA COVID-19 vaccination among U.S. adults

D. Peake, T. Shimabukuro, J. Baggs, 2022, Vaccine.